International Journal of Medical and Pharmaceutical Research
2024, Volume-5, Issue-3
Original Research Article
Risk Factors for Relapse in Patients with Inflammatory Bowel Disease A Prospective Longitudinal Study
Published
June 23, 2024
Abstract

Background: Inflammatory Bowel Disease (IBD), which includes Crohn's Disease (CD) and Ulcerative Colitis (UC), is characterized by chronic inflammation of the gastrointestinal tract and a relapsing-remitting disease course. Understanding the risk factors for relapse can help in tailoring management strategies for patients. Methods: This prospective longitudinal study involved 500 patients with IBD, split equally between CD and UC, who were in remission at study onset. Over two years, data on genetic markers, environmental and lifestyle factors, microbiome composition, medication adherence, and psychological stress were collected and analyzed to identify their association with disease relapse. Results: Significant predictors of relapse included the presence of the NOD2/CARD15 genetic marker in CD (28% presence, p < 0.001), smoking (OR 2.9, p < 0.001), highfat diet (OR 2.3, p < 0.001), alterations in microbiome composition (p < 0.001), low medication adherence (HR 3.1, p < 0.001), and high psychological stress (HR 2.7, p < 0.001). These factors were independently and cumulatively significant in multivariable analyses. Conclusion: The study highlights the complex interplay of genetic, environmental, microbial, and psychosocial factors in the relapse of IBD. Addressing these factors through targeted interventions could substantially reduce the burden of disease relapses.

Recommended Articles
Loading Image...
Volume-5, Issue-3
Citations
2316 Views
464 Downloads
Share this article
License
Copyright (c) International Journal of Medical and Pharmaceutical Research
pdf Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All papers should be submitted electronically. All submitted manuscripts must be original work that is not under submission at another journal or under consideration for publication in another form, such as a monograph or chapter of a book. Authors of submitted papers are obligated not to submit their paper for publication elsewhere until an editorial decision is rendered on their submission. Further, authors of accepted papers are prohibited from publishing the results in other publications that appear before the paper is published in the Journal unless they receive approval for doing so from the Editor-In-Chief.
IJMPR open access articles are licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. This license lets the audience to give appropriate credit, provide a link to the license, and indicate if changes were made and if they remix, transform, or build upon the material, they must distribute contributions under the same license as the original.
Logo
International Journal of Medical and Pharmaceutical Research
About Us
The International Journal of Medical and Pharmaceutical Research (IJMPR) is an EMBASE (Elsevier)–indexed, open-access journal for high-quality medical, pharmaceutical, and clinical research.
Follow Us
© Copyright IJMPR | All Rights Reserved